IntegraGen Announces Publication in Oncotarget Showing Association of miR-31-3p Expression Levels with Progression-Free Survi...
October 09 2017 - 2:00AM
Business Wire
Regulatory News:
IntegraGen (Paris:ALINT), a company specializing in the
transformation of data from biological samples into genomic
information and diagnostic tools for oncology, today announced that
results from an analysis of miR-31-3p expression in tumor samples
from patients enrolled in the NEW EPOC clinical trial have been
published online in Oncotarget. The paper entitled “Association
between miR-31- 3p expression and cetuximab efficacy in patients
with KRAS wild-type metastatic colorectal cancer: a post-hoc
analysis of the New EPOC trial” confirms the relationship between
miR-31-3p expression and the efficacy of anti-EGFR treatment.
“This publication confirms that analyzing miR-31-3p expression
levels in patients with RAS wild-type metastatic colorectal cancer
can be used as a complementary diagnostic tool to help identify
patients who will benefit from targeted anti-EGFR therapy,” stated
study co-author Prof. John Bridgewater a Medical Oncologist at
University College London Cancer Institute and an Investigator for
the New EPOC Study. “We are extremely pleased to be able to
continue to publish clinical data from the New EPOC trial which
provides clinicians with additional insight on tailoring
therapeutic approaches to better treat patients with metastatic
colorectal cancer.”
“This peer-reviewed publication contributes to the growing
evidence of the benefit of measuring miR-31-3p in tumors from
patients with metastatic colorectal cancer,” said Yann
Gaston-Mathé, Director of Molecular Diagnostics at IntegraGen.
“This is one more step towards the realization of the benefits of
precision medicine as well as generating adoption and coverage for
miR-31-3p expression testing.”
IntegraGen has recently announced the CE-IVD Marking and
European commercial launch of the company’s miRpredX 31-3p kit, a
simple ready-to-use kit designed to quantify the expression of the
miR-31-3p in formalin-fixed, paraffin-embedded (FFPE) tumor
samples. Earlier this year IntegraGen also announced a licensing
agreement with the CERBA laboratories for the development of a
laboratory developed test which measures the expression of the
miR-31-3p.
About the miRpredX 31-3p Test
The miRpredX 31-3p test is the first positive theranostic test
for patients with metastatic colorectal cancer (mCRC). The miRpredX
31-3p test predicts the potential clinical benefits associated with
first-line anti-EGFR therapy compared to anti-VEGF therapy or when
second or further lines of treatment with anti-EGFR therapy is
beneficial versus chemotherapy alone for patients with RAS wild
type (WT) mCRC. A recent study demonstrated that expression of the
miR-31-3p is a predictive marker of both overall survival and
response to treatment with anti-EGFR therapy1. The study also
demonstrated that patients whose expression level is measured below
the pre-defined threshold treated with FOLFIRI plus cetuximab have
a one year longer median overall survival, a 40% reduction in
mortality risk, and a better treatment response compared to
patients treated with FOLFIRI plus bevacizumab.
For more information on the miRpredX 31-3p test visit
www.miRpredX.com.
About Metastatic Colorectal Cancer
Colorectal cancer is third most common cancer in men and second
most common in women with over 1.3 million new cases annually on a
worldwide basis. This includes over 345,000 new cases in Europe and
135,000 new cases in the United States on an annual basis2. An
estimated 25% of patients with colorectal cancer will present with
metastatic disease at the time of diagnostic with up to an
additional 50% of patients developing mCRC following initial
diagnosis3. An estimated 694,000 deaths from CRC occur worldwide
every year, accounting for 8.5% of all cancer deaths and making it
the fourth most common cause of death from cancer2. Approximately
50% of patients with metastatic colorectal cancer, representing
347,000 patients worldwide, have RAS wild-type tumors4.
1. Laurent-Puig P, Grisoni ML, Heinemann V, et al. MiR-31-3p as
a predictive biomarker of cetuximab efficacy effect in metastatic
colorectal cancer (mCRC) patients enrolled in FIRE-3 study. J Clin
Oncol. 2016; 34 (suppl; abstr 3516).
2. World Health Organization – International Agency for Research
on Cancer, 2017
3. Van Cutsem E, Cervantes A, Nordlinger B, Arnold D for the
ESMO Guidelines Working Group. Metastatic colorectal cancer:
ESMO Clinical Practice Guidelines for diagnosis, treatment and
follow-up. Ann Oncol. 2014; 25 Suppl 3:iii1-9.
4. Peeters M, et al. Prevalence of RAS mutations and individual
variation patterns among patients with metastatic colorectal
cancer: A pooled analysis of randomised controlled trials. Eur J
Cancer. 2015; 51:1704-13.
About IntegraGen
IntegraGen is a company specializing in deciphering the human
genome and producing relevant and easily interpretable data for
academic and private laboratories. IntegraGen’s oncology efforts
provide researchers and clinicians with sophisticated tools for
analysis and therapeutic individualization of treatment approaches
allowing them to tailor therapy to the genetic profiles of
patients. As of December 31, 2016, IntegraGen had 38 employees and
had generated revenue of €6.0 million in 2016. Based in Evry
Genopole, IntegraGen also has an U.S. office in Cambridge,
Massachusetts. IntegraGen is listed on Euronext Growth (ISIN:
FR0010908723 - Ticker: ALINT - PEA-SME).
For more information, visit www.integragen.com
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171008005050/en/
IntegraGenBernard COURTIEUPresident and CEOorLaurence
RIOT LAMOTTEChief Financial Officercontact@integragen.comTel.: +33
(0)1 60 91 09 00orNewCapInvestor RelationsLouis-Victor
DELOUVRIERintegragen@newcap.euTel.: +33 (0)1 44 71 98 53
Integragen (EU:ALINT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Integragen (EU:ALINT)
Historical Stock Chart
From Jul 2023 to Jul 2024